# US 2022/0031635 A1 · Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031635 A1
- Document ID: US20220031635A1
- Status: Published application
- Kind: A1
- Application number: 17/388,061
- Filed: 2021-07-29
- Published: 2022-02-03
- Earliest claimed: 2020-07-28
- Assignees: Wsmef LLC
- Applicants: Wsmef, LLC
- Inventors: Clint Sorensen; Melanie Montgomery; Matt Smith
- Web page: https://patentgrep.com/patent/US20220031635A1

## CPC

- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 36/3482: {Cannabis}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure provides a technology for managing elevated cytokine levels and the risk of cytokine storm in viral infection, exemplified by SARS-CoV-2, the virus that causes COVID-19. A special mixture of cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) is extracted from the flowers and leaves of Cannabis sativa (industrial hemp). The purified oil is packed with a surfactant into small micelles, which considerably increases absorption by the gastrointestinal tract, resulting in higher potency and a more rapid onset of action. Daily treatment of patients infected with SARS-CoV-2 reduces the circulating level of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) by 25 to 50% or more. The level of circulating markers of ongoing inflammation, such as C reactive protein (CRP) and/or erythrocyte sedimentation rate (EST) are also reduced. This lowers the risk that the treated patient will suffer the adverse consequences of a cytokine storm, potentially helping the patient to clear the virus and return to good health.

## Claims

### Claim 1

A method of reducing circulating levels of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) in a human subject in need thereof by 25% to 50%, the method comprising:
administering to the subject a course of therapy that includes oral consumption of a cannabinoid preparation periodically or every day for at least 20 days;
wherein cannabinoids contained in the preparation are in a form that consists essentially of micelles suspended in an aqueous solvent;
wherein the micelles in the preparation comprise one or more amphipathic compounds combined with full-spectrum hemp oil;
wherein the preparation has a cannabinoid content of 0.1 to 1.0% by weight,
wherein the cannabinoid content is a mixture of cannabinoids that includes at least 70% cannabidiol (CBD), at least 2% tetrahydrocannabivarin (THCV), at least 3% cannabidivarin, and less than 1% Δ9-tetrahydrocannabinolic acid (THC);
wherein the course of therapy with the cannabinoid preparation results in a reduction in the circulating levels of the subject of both the TNFα and the IL-6.

### Claim 2 (depends on 1)

The method of claim 1, which is a method of decreasing the risk of cytokine storm in a subject who has signs of infection with SARS-CoV-2 (the virus that causes COVID-19).

### Claim 3 (depends on 2)

The method of claim 2, wherein the course of therapy with the cannabinoid preparation results in a reduction in the circulation of the subject of C reactive protein (CRP) and/or erythrocyte sedimentation rate (EST).

### Claim 4 (depends on 2)

The method of claim 2, further comprising measuring time-progression of the circulating level of C reactive protein, TNFα, IL-6, or a combination thereof during and/or after administration of the course of therapy.

### Claim 5 (depends on 1)

The method of claim 1, which is a method of treating a viral infection in the subject that causes an increase in circulating levels of pro-inflammatory cytokines.

### Claim 6 (depends on 1)

The method of claim 1, which is a method for treating joint pain in the subject.

### Claim 7 (depends on 1)

The method of claim 1, which is a method for treating Type*II diabetes.

### Claim 8 (depends on 2)

The method of claim 2, wherein the course of therapy also improves sleep quality in the subject by increasing the amount of a night's sleep of the subject that is spent in deep sleep by at least 30 minutes.

### Claim 9 (depends on 2)

The method of claim 2, wherein the course of therapy also reduces anxiety in the subject.

### Claim 10 (depends on 2)

The method of claim 2, wherein the cannabinoid content of the preparation contains the following components: at least 70% cannabidiol (CBD), at least 2% tetrahydrocannabivarin (THCV), at least 5% cannabidivarin (CBDV), and at least 2% cannabigerol (CBG).

### Claim 11 (depends on 2)

The method of claim 2, wherein the one or more amphipathic compounds in the micelles are selected from polyethylene glycol (PEG) 40 hydrogenated castor oil, polyethylene glycol-phosphatidylethanolamine (PEG-PE), poly(N-vinyl pyrrolidone) (PVP). poly(N-isopropylacrylamide) (pNIPAM), poloxamer 407, poloxamer 188, poloxamer 85, and tocopherol methoxypolyethylene glycol succinate (TPGS).

### Claim 12 (depends on 2)

The method of claim 2, wherein the cannabinoid preparation has an onset of action within 15 minutes of consumption of the preparation by the subject.

### Claim 13 (depends on 2)

The method of claim 2, wherein at least 40% of the cannabinoids in the preparation have been absorbed into the circulation of the subject within 4 hours of consumption.

### Claim 14 (depends on 2)

The method of claim 2, wherein the preparation further comprises at least 1% cinnamon oil and/or at least 1% clove oil in micelle form.

### Claim 15

A therapeutic preparation of full spectrum hemp oil formulated for oral consumption by a human patient infected with SARS-CoV-2 (the virus that causes COVID-19),
wherein the preparation comprises a mixture of cannabinoids that together constitute 0.1 to 1.0% by weight of the preparation,
wherein the cannabinoids in the preparation are in a form that consists essentially of micelles having a diameter of 10 to 100 microns,
wherein the micelles comprise one or more amphipathic compounds combined with full-spectrum hemp oil;
wherein the cannabinoid mixture contains the following components: at least 70% cannabidiol (CBD), at least 2% tetrahydrocannabivarin (THCV), at least 5% cannabidivarin, and less than 1% Δ9-tetrahydrocannabinolic acid (THC); and
wherein the amount of cannabinoids, the blend of cannabinoids in the mixture and the size of the micelles in the preparation are selected so that the preparation is effective in reducing circulating levels of both tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) in the subject by at least 25% when consumed daily by the patient for at least 20 days.

### Claim 16 (depends on 15)

The therapeutic preparation of claim 15, wherein the components of the therapeutic preparation further comprise cinnamon oil that is present in the preparation at a concentration of at least 1% by weight.

### Claim 17 (depends on 16)

The therapeutic preparation of claim 16, wherein the components of the therapeutic preparation further comprise clove oil that is present in the preparation at a concentration of at least 1% by weight.

### Claim 18 (depends on 15)

The therapeutic preparation of claim 15, which has an onset of action within 15 minutes of consumption by the patient.
